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Purpose of the study
Treatment-experienced HIV-infected patients with limited
therapeutic options continue to receive a partially sup-
pressive treatment regimen pending the availability of two
new antiretroviral drugs. We analyzed the viro-immuno-
logical and resistance data of 38 outpatients.
Methods
Major enrollment criterion was the administration of
maraviroc, enfuvirtide, raltegravir, etravirine, darunavir/r
or tipranavir/r, alone or in combination, in the latest
antiretroviral regimen, decided upon the last genotypic
RNA resistance test. This allowed us to assess the geno-
typic sensitivity score (GSS) at the same time. We also
recorded previous presence of specific mutations in all
available genotypic resistance tests, their persistence in
time and their correlation to the last GSS.
Summary of results
Undetectable viral load was obtained in 64% of patients
without difference between GSS classes (HIV-RNA
median value <50 cp/ml in any class); we also reported a
mild increase in CD4 count (6 months median of 290/μl
for GSS1, 299/μl for GSS2 and 367/μl for GSS3). This was
not significantly related to GSS considering either GSS1
vs. 2 vs. 3 or GSS1 vs. 2 plus 3. Our data showed persist-
ence of specific mutations for NRTI: 184IV, 210W, 215FY,
219EQ (over 50% in every test) and 67N in almost 70%
of all tests; for NNRTI: 103N and 181CIV in over 25% of
cases with higher tendency to persist for repeated tests; for
PI: 10FIRVC, 36ILV, 41L, 46IL, 54VLAMTS, 71OVT,
82AFTSLI, 90M (about 50% in every test) and 63P in
almost 70–80% of all cases. This frequency (weighted for
the number of tests) was correlated to GSS and revealed a
particular pattern for the majority of these mutations: a
higher prevalence when related to GSS2 vs. GSS1 and 3.
Conversely, NNRTI 181CIV and NRTI 210W showed
larger numbers in GSS1 and 3.
Conclusion
Starting an antiretroviral regimen with drugs from the
newest active classes can offer viro-immunologic success
either with GSS1, 2 or 3. Lack of statistical difference can
be explained with a low number of enrolled patients and
different viro-immunologic conditions at baseline (higher
viral loads and lower CD4 for GSS2 and 3). High fre-
quency for specific mutations confirms the key role of
some mutations acquired following the exposure to cer-
tain drugs and their persistence through multiple changes
of drug regimen. The association between GSS2 and
mutation frequency (time weighted) could be linked to
patients with better compliance and long persistence of
key mutations, which appeared after a long drug expo-
sure.
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